L.A. County-based Xencor Inc. is expanding its operations into San Diego, the company announced Thursday.
The biopharma’s new San Diego facility is now open in Del Mar Heights and staffs 17 employees, with plans to hire four more staff in the near future.
The company, which is developing engineered monoclonal antibodies to help treat autoimmune diseases, asthma, allergic diseases and cancer, will also be expanding its team headquartered in Monrovia, California, according to a company news release.
“We’re expanding our team quickly and it is a great sign of the future ahead as we prepare to advance additional candidates using Xencor's XmAb bispecific technology into the clinic by the end of 2017,” said Bassil Dahiyat, CEO at Xencor, in a statement.
Xencor currently has 10 product candidates engineered with Xencor's XmAb technology in clinical development internally and with partners.
The expansion in both sites enables Xencor to focus on its clinical-stage drug development, and broaden its pipeline of XmAb drug candidates.